Voices
Renee Gala Shares What FDA’s HER2+ GEA Treatment Approvals Mean for Patients
Renee Gala/LinkedIn

Renee Gala Shares What FDA’s HER2+ GEA Treatment Approvals Mean for Patients

Jazz Pharmaceuticals shared on LinkedIn:

“For patients with HER2-positive gastroesophageal adenocarcinoma (GEA), the start of treatment is a defining moment. Today represents another important moment for this patient population.

The U.S. FDA has approved 2 new first-line treatment regimens for this disease, establishing a new standard of care and bringing innovation to patients when it can have the greatest impact.

Our President and CEO, Renee Gala, shares what this milestone means for patients, for our teams and for Jazz.”

You can also read:

FDA Approves Ziihera With and Without Tislelizumab Plus Chemotherapy for First-Line HER2-Positive Gastroesophageal Adenocarcinom

Renee Gala Shares What FDA's HER2+ GEA Treatment Approvals Mean for Patients

cancer FDA HER2-positive gastroesophageal adenocarcinoma HER2-positive GEA HER2+ gastroesophageal adenocarcinoma HER2+ GEA Jazz Pharmaceuticals OncoDaily Oncology Renee Gala